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Background: This study investigates the effects of human bone marrow-derived mesenchymal stem cell (hMSC) on
migration and proliferation ability of hepatocellular carcinoma (HCC) with high- and low-metastatic potential.
Methods: The hMSC and transforming growth factor-β1 (TGFβ-1) gene infected hMSC were co-cultured with
hepatoma cells. The ability of cells migration was assessed by Transwell assay. The ability of cells proliferation was
detected using CCK-8 assay. The mice were engrafted with hMSC and TGFβ-1 gene infected hMSC, respectively,
after hepatoma cells inoculation 15 days, twice a week for 6 weeks successively. The tumor inhibition rate was
calculated. TGFβ-1, osteopontin (OPN), and programmed cell death protein 4 (PDCD4) genes expression of
hepatoma cells were detected by quantitative real-time polymerase chain reaction (qPCR) before and after
co-cultured experiments.
Results: TGFβ-1 infected hMSC or hMSC co-culture with hepatoma cells groups can significantly promote
hepatoma cells proliferation (P < 0.05). The migration numbers of hepatoma cells with TGFβ-1 infected hMSC
co-culture groups were significantly reduced compared with the other two groups (P < 0.05). The tumors weight
inhibition rates of MHCC97-H and MHCC97-L animal models were the highest in the third week by hMSC engraftment.
But the highest tumor inhibition rate of MHCC97-H animal models was observed in the fourth week and MHCC97-L
animal models in the fifth week after TGFβ-1 infected hMSC engraftment. OPN gene relative quantitative expression of
hepatoma cells was significantly down-regulated after co-cultured with hMSC and TGFβ-1 gene infected hMSC groups
(P < 0.05). TGFβ-1 gene relative quantitative expression of MHCC97-H and MHCC97-L cells was significantly up-regulated
after co-cultured with TGFβ-1 gene infected hMSC groups (P < 0.05). PDCD4 expression had no statistical differences
among groups.
Conclusions: hMSC and TGFβ-1 gene infected hMSC can promote hepatoma cells proliferation and inhibit hepatoma
cells migration. hMSC and TGFβ-1 gene infected hMSC exhibit anti-tumor activity in a time-dependent manner. TGFβ-1
cytokine may be the main factor in HCC proliferation. OPN makes a significant contribution to the changes of hepatoma
cells metastasis.
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Hepatocellular carcinoma (HCC) is one of the most
common cancers with poor prognosis and high recur-
rence rate, and metastatic recurrence is the major obs-
tacle to improve the prognosis of HCC patients. Human
bone marrow-derived mesenchymal stem cell (hMSC) is a
type of adult stem cells with multilineage differentiation
potential. Previous studies have reported that hMSCs
could inhibit the growth of hepatocellular carcinoma tis-
sue and repair the impaired liver tissue. Hence, hMSCs
become a hot-spot for the treatment of hepatocellular car-
cinoma [1, 2]. However, there is also the opposite view.
Researchers believed that hMSC can promote the growth
and metastasis of hepatocellular carcinoma cells [3]. Fur-
thermore, the metastasis of hepatocellular carcinoma is a
key factor for its prognosis, and it is important to extend
the life-span of HCC patients by observing the effect of
hMSCs on HCC metastatical ability. Enhancing hMSC re-
sistance ability to HCC tissue and metastatic potentials by
genic engineering technology has been regarded as a feas-
ible way. It has been reported that transforming growth
factor beta (TGFβ) is a multifunctional cytokine family,
which mainly plays roles in regulating cell proliferation,
differentiation, and embryo development, promoting the
formation of extracellular matrix and inhibiting immune
response. Among the members in this family, serum
TGFβ-1 is a principal isoform in humans, and it is closely
associated with the occurrence and development of
tumor. TGFβ-1 plays dual roles in inhibiting and promot-
ing tumor growth. At the early stage of tumorogenesis,
TGFβ-1 inhibited normal cell growth and tumorogenesis
by suppressing G1/S phase transition [4, 5]. However, the
tumor would not be sensitive to TGFβ-1 mediated
growth inhibition with the development of tumor. As a
tumor growth stimulating factor, TGFβ-1 plays an im-
portant role in tumor growth, invasion, and metastasis.
Therefore, in order to investigate intervention effects of
hMSC to hepatocellular carcinoma tissue, in this study,
TGFβ-1 was infected into human bone marrow-derived
mesenchymal stem cells using a transgenic technology
based on the biological characteristics of TGFβ-1. Our
study mainly focuses on the effects of TGFβ-1 infected
hMSC on HCC cells with high- and low-metastatic po-
tentials, and the roles of hMSC in HCC progression
in vitro are determined. Our data provide a preliminary
exploration of the treatment against hepatocellular car-




Fetal calf serum (FCS) was purchased from PAN (Aidenbach,
Germany), and trypsin tenfold was supplied by PAA
(Pasching, Austria). Dulbecco’s modified eagle’s medium(DMEM) was supplied by Dulbecco’s and α-minimum es-
sential medium (MEM) was supplied by ATCC.
Cell lines
Human hepatocellular carcinoma cell lines with high-
metastatic potential (MHCC97-H) and low-metastatic po-
tential (MHCC97-L) were provided by the Liver Cancer
Institute of Fudan University (Shanghai, China). hMSC were
purchased from the Cyagen Biotech Co. Ltd. (Guangzhou,
China).
Animals
Thirty-six 6-week aged specific-pathogen-free (SPF) grade
nude mice of the Balb/c strain (female to male ratio = 1),
each weighing 14–17 g, were purchased from the Labora-
tory Animal Center of National Institutes for Food and
Drug Control (Beijing, China). Animals were kept within
the animal care facility of the Peking University Health
Science Center. The experiments conform to the Guide
for the Care and Use of Laboratory Animals published by
the US National Institutes of Health (NIH Publication No.
85–23, revised 1996). The housing and care and proce-
dures in the study were performed in accordance with the
guidelines and regulations composed by the Animal Care
Committee of the University of the Peking University
Health Science Center and approved by the Institutional
Animal Care and Use Committee of the Peking University
Health Science Center, China.
Hepatoma cells and hMSCs culture
MHCC97-H and MHCC97-L cells were routinely cultured
on 75-cm2 culture flasks in high-glucose DMEM supple-
mented with 10 % FCS, 1 % L-glutamine, and 1 % penicil-
lin/streptomycin at 37 °C and 5 % CO2 in a humidified
incubator. The medium was replaced at 50 % of cell con-
fluence. Tumor cells were passaged once (80 % of cell
confluence), cultured for a further 2 days, and then trypsi-
nized for subsequent implantation studies. Tumor cells
from the same passage were used for all the implantation
experiments.
The hMSCs were washed once with α-MEM and seeded
at a concentration of 1 × 106 cells/cm2 per 100-mm cell
culture dish (Corning, Corning, NY) in α-MEM media
containing 10 % fetal calf serum, nonessential amino acids
(Cellgro, Herndon, VA), and pyruvate (Invitrogen, Carlsbad,
CA) and cultured at 37 °C in 5 % CO2. After 48 h, nonad-
herent cells were removed, fresh media was added, and
the culture was maintained for 7 days. Before infusion,
cells were washed twice with phosphate buffer solution
(PBS) and harvested and using magnetic beads (Miltenyi
Biotech, Auburn, CA). Cells were resuspended at a con-
centration of 5 × 106cells/ml. Expanded cells that displayed
morphological, immunophenotypical, and differentiation
properties of mesenchymal stem cells were identified
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differentiation (CD) of hMSC. Cy3 and hoechst33342
(Sigma) labeled hMSC to observe proliferation under
fluorescence microscopes. Cy3 excitation wavelength is
550 nm, and emission wavelength is 565 nm. hoechst33342
excitation wavelength is 350 nm, and emission wavelength
is 461 nm.
TGFβ-1 gene infecting hMSC
First is the construction of retroviral vector. The pLV.
EX3d.P/neo-EF1A > TGFβ-1 > IRES/eGFP shuttling plas-
mid was constructed using Gateway technology. Overlap
extension quantitative real-time polymerase chain reaction
(qPCR) was used to amplify attB1-Kozak-TGFβ-1-attB2.





quently, pDown-TGFβ-1 plasmid and pLV.EX3d.P/neo-
EF1A > TGFβ-1 > IRES/eGFP plasmid were constructed.
The positive clone was screened using colony PCR, and
the positive plasmids were further sequenced.
Second, lentivirus was produced. Totally, 5 × 106 well-
growth 293FT cells were counted and seeded into a 10-cm
culture dish overnight. The old medium was removed,
and 5 ml of DMEM containing 10 % FCS was added. Plas-
mid pLV.EX3d.P/neo-EF1A > TGFβ-1 > IRES/eGFP was
added into the culture medium. The medium was sub-
stituted 24 and 48 h after the infection, respectively. The
viruses were collected and concentrated 72 h after the in-
fection, and the viral titre was further measured. More-
over, the cells were stained with crystal violet after drug
screening.
Third is the TGFβ-1 infecting of hMSC. One milliliter
of fresh complete medium of hMSCs was added into
each well. Totally, 30 μl of viruses was used to infect the
cells in one well, and the other well was set as blank
control. The cells were cultured after mixing. The com-
plete medium containing viruses was removed after 16 h
of infection, and the cells were washed with PBS twice.
The cells were continuously cultured for 72 h, and the
infection efficacy was observed using a fluorescence
microscope. The cells were used to perform PCR and
western blot when the infection rate met the require-
ments. And hMSCs were observed using immunofluor-
escence before and after the infection.
Assessment of tumor cell proliferation
Cell counting kit (CCK-8) assay is used to evaluate the
proliferation ability of hepatoma cells. Dimethyl sulfox-
ide (DMSO) in 3-(4, 5)-dimethylthiahiazo(-z-y1)-3,5-di-
phenytetrazoliumromide (MTT) assay would affect the
culture membrane; therefore, we detected cell proliferationusing CCK-8 assay. Totally, 2 × 103 tumor cells (75 μl)
were seeded into each upper chamber in a 96-well plate
after the hMSC cells were adhered to the lower chamber.
After 48 h of co-culture, the medium in each well was sup-
plied to 80 μl in total, and 8 μl of CCK-8 was added into
each upper chamber well. The mixture was incubated at
37 °C for 4 h. After the incubation, the optical density
(OD) at 490 nm was detected using an ELISA reader. The
experiment is repeated for six times.
Assessment of tumor cell migration
The basement membrane (BM) is a specialized form of
extracellular matrix (ECM), which is a major barrier to
tumor cells during metastasis. Transwell assay is used to
evaluate that the hepatoma cells break through the base-
ment membrane (or migration) ability. ECM gel (Sigma,
Swiss) was precooled at 4 °C for 2 h, and 50 μl of ECM
gel was added into the upper chamber. The chamber
was incubated at 37 °C in a humidified atmosphere of 5 %
C02 until the gel was solidified. The tumor cells were cul-
tured with serum-free medium for 24 h and were counted
after digestion. Moreover, these cells were resuspended
using medium supplemented with 0.1 % FCS, and the cell
concentration was adjusted to 1 × 106 cells/ml. Totally,
10,000 human mesenchymal stem cells were seeded in the
lower chamber using 500 μl of medium supplemented
with 20 % FCS, and 100 μl of hepatoma cells suspension
at a concentration of 1 × 106 cells/ml was added into the
upper chamber. ECM gel chamber was incubated at 37 °C
in a humidified atmosphere of 5 % CO2 for 36 h. The cells
on the upper surface of chamber were removed. Next,
500 μl of MTT (0.5 mg/ml) was added into each well of a
24-well plate. The chambers were immersed in medium
at 37 °C for 4 h. Then, 500 μl of DMSO was added into
each well, and the chambers were immersed in DMSO
and oscillated for 10 min. Finally, formazan crystal was
completely dissolved. The chambers were got out, and
100 μl DMSO was transferred into each well of a 96-well
plate. The tumor cells on ECM gel and in upper chamber
were removed using cotton swabs. The tumor cells were
stained using 0.1 % crystal violet. The tumor cells were
counted using a common microscope, and the chamber
was everted to clearly observe the tumor cells in the
lower chamber. The experiment is repeated for six times.
Animal procedures
Mice were randomly assigned into one of two groups
(n = 15 animals per group) in MHCC97-H and MHCC97-
L group, and all mice were weighed and numbered. The
mice in the experimental group were engrafted with
hMSCs (5 × 105 cells per mouse) via the tail vein 15 days
after inoculation of tumor cells, twice a week for 6 weeks
successively, while the animals in the control group were
injected with hMSC culture medium (0.2 ml per mouse)
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tumor size was measured using an electronic digital cali-
per once every 4 days after hMSC engraftment. After 2, 3,
4, 5, and 6 weeks of tumor cell inoculation, the mice were
killed and the tumors were collected in their entirety. The
tumor weight and body weight of mice were measured.
The tumor inhibition rate was calculated using the fol-
lowing formula:




E (g), mean tumor weight in the experiment group; C (g):
mean tumor weight in the control group.
Relative quantification using quantitative RT-PCR analysis
The primer sequences were obtained from GenBank
database and synthesized by Cyagen Biotech Co. Ltd.
(Guangzhou, China). The primer sequences of these genes
were as follows (see Table 1).
β-Actin and GAPDH was used for normalization. To-
tally, 3 × 104 hMSC cells that were seeded into the lower
chamber of a 12-well plate after MHCC97-H cells were
adhered to the upper chamber. After 48 h of co-culture,
cells of the upper chamber were harvested for PCR detec-
tion. Total RNA was extracted, and cDNA was obtained
using RevertAid ™ M-MLV RT system and Oligo (dT).
The specific cDNA was amplified using PCR, and the pro-
file was as follows: 95 °C for 5 min, followed by 30 cycles
of 94 °C for 30 s, 58 °C for 30 s, and 72 °C for 30 s, with a
final extension at 72 °C for 10 min. The PCR products were
semi-quantitatively analyzed using gel electrophoresis.
Statistics
Data were analyzed using Statistical Product and Service
Solutions software (SPSS, version 16.0). Results were
expressed as mean ± standard error of the mean (SEM).
Differences between two groups were evaluated with the
unpaired Student’s t test. Analysis of variance (ANOVA)
was used to determine statistical differences. A p value <
0.05 was considered significant.
Results
Mesenchymal stem cells identification results
hMSCs growth curve was drawn from the first day they
recovered. The morphology, growth and proliferation ofTable 1 Invasion and proliferation-related gene relative quantitative
OPN TGFβ-1
MHCC97-H (%) MHCC97-L (%) MHCC97-
Medium 100 100 100
hMSC 75.23 83.14 157.5
TGFβ-1/hMSC 51.03 49.11 206.5the cells were observed during continuous culture in vitro,
and doubling time of cells was calculated. According to
growth curve of experiment data to calculate the cells,
doubling time is 26 h. After pass-generation tests for five
times, the cells still has the vigor. At a ratio of 1:2 cells in-
oculated, cells can be covered within 72 h. In morpho-
logical observation under microscope and fluorescence
microscopes (Fig. 1a, b), hMSCs are spindle-shaped, the
size are uniform, and the polarity is arranged. Distribution
of collagen in the cytoplasm and the nucleus shape are
normal. The expressions of surface antigens CD29, CD44,
and CD105 on these cells were detected by Flow Cytome-
try, and cells did not express CD45 and CD14 surface
antigens. So, the experimental hMSC conformed to stan-
dards made by The International Society for Cellular
Therapy position statement (2006) [6].
TGFβ-1 gene infection of hMSC
First, morphological change of infected hMSCs was ob-
served. Green fluorescent protein (GFP) was used as a
reporter gene, and the target gene infected hMSC was
observed under the fluorescence microscope compared
with without gene infected hMSC (Fig. 2a,b).
Second, TGFβ-1 gene expression changes of hMSC
were detected by qPCR before and after the infection
target gene. hMSC and hMSC infected GFP are the con-
trol groups; hMSC infected TGFβ-1 is the experimental
group (Fig. 3).
Figure 3 showed that the TGFβ-1 expression of hMSC
infected TGFβ-1 gene group was higher than that of
control groups ((#p < 0.001), and TGFβ-1 expression of
experimental group was about seven times as that of
blank control group. But the difference between hMSC
and hMSC infected GFP group had no statistical signifi-
cance (p > 0.05). It has been indicated that the hMSC in-
fected TGFβ-1 gene was successful and can proceed to
the next step.
Assessment of hMSC on hepatoma cells proliferation
The proliferation ability effects of hMSC and TGFβ-1
infected hMSC on hepatoma cells (MHCC97-H and
MHCC97-L) were detected using CCK-8 (Cell Counting
Kit-8) assay. hMSC and TGFβ-1 infected hMSC co-
culture with hepatoma cells groups served as experimen-
tal groups. MHCC97-H and MHCC97-L groups served
as control groups (Figs. 4 and 5).expression of hepatoma cells
PDCD4
H (%) MHCC97-L (%) MHCC97-H (%) MHCC97-L (%)
100 100 100
4 129.04 69.61 64.33
2 176.52 233.31 125.45
Fig. 1 hMSC type I collagen Cy3 immunofluorescence staining and nucleus hoechst33342 staining. a Red represents the Cy3 immunofluorescence
staining positive cells skeleton. hMSCs are spindle-shaped, the size are uniform, and the polarity is arranged. b Blue represents the hMSC nucleus. The
nuclei are round, oval shape. Scale bars = 50 μm for (a–b)
Li et al. European Journal of Medical Research  (2015) 20:56 Page 5 of 11As shown in Figs. 4 and 5, hMSC can promote
MHCC97-H and MHCC97-L cells proliferation, espe-
cially TGFβ-1 gene infected hMSC.
Assessment of hMSC on hepatoma cells migration
The two hepatoma cells were co-cultured with hMSC and
TGFβ-1 infected hMSC, respectively, and hepatoma cells
with culture medium acted as the control groups. The
breaking through basement membrane migratory hepa-
toma cells were stained using 0.1 % crystal violet. The mi-
gration of hepatoma cells was evaluated by means of a
quantitative counting procedure (CCK-8) (Figs. 6 and 7).
The migration numbers of MHCC97-H cells with TGFβ-
1 infected hMSC co-culture groups were significantly re-
duced compared with the control group (*p < 0.05).
The migration numbers of MHCC97-L cells with
TGFβ-1 infected hMSC co-culture groups were signifi-
cantly reduced compared with the other two groups
(**p < 0.01), and TGFβ-1 infected hMSC co-culture with
MHCC97-L cells group was significantly reduced com-
pared with hMSC co-culture group (*p < 0.05).Animal model experiment results
Firstly, effects of hMSC on transplanted tumors in nude
mice produced by inoculation of MHCC97-H and
MHCC97-L cells were investigated. The experiment
lasted for 6 weeks. According to the tumor tissue speci-
mens’ weight in vitro before and after hMSC interven-
tion, the tumor weight inhibition rate was calculated
(Fig. 8).
It was observed that the highest tumor inhibition rate
was observed 3 weeks after hMSC engraftment, and the
tumor inhibition rate gradually reduced with the pro-
longation of time.
Secondly, effects of TGFβ-1 infected hMSC on trans-
planted tumors in nude mice produced by inoculation of
MHCC97-H and MHCC97-L cells were investigated.
The experiment lasted for 6 weeks. According to the
tumor tissue specimens’ weight in vitro before and after
TGFβ-1 infectedhMSC intervention, the tumor weight
inhibition rate was calculated (Fig. 9).
Compared with the hMSC without TGFβ-1 gene trans-
fection, the highest tumor inhibition rate of MHCC97-H
Fig. 3 TGFβ-1 expression changes were detected using qPCR before
and after hMSC infected target gene. The TGFβ-1 expression of
hMSC infected TGFβ-1 gene group was higher than that of control
groups (#p < 0.001). But the difference between hMSC and hMSC
infected GFP group had not statistical significance (p > 0.05)
Fig. 2 hMSC imaging of hMSC infected TGFβ-1 gene with reporter
gene GFP observed under fluorescence microscope and inverted
microscope. a hMSCs which have been penetrated by the green
fluorescent protein (GFP) begin to glow with bright green. Original
magnification. b Cells arranged regularly. The shape of gene-transduced
hMSC was essentially the same as no-genetically modified cells.
Original magnification. Scale bars = 100 μm for (a), 50 μm for (b)
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TGFβ-1 infected hMSC engraftment, and the tumor in-
hibition rate gradually reduced with the prolongation of
time. The highest tumor inhibition rate of MHCC97-L
animal models was observed in the fifth week after TGFβ-
1 infected hMSC engraftment, and the tumor inhibition
rate gradually reduced with the prolongation of time.
Relative quantification using real-time PCR analysis
MHCC97-H and MHCC97-L cells served as control
groups, and osteopontin (OPN), TGFβ-1, and programmed
cell death protein 4 (PDCD4) gene expression levels in
hepatoma cells was set as 100 %. So, OPN, TGFβ-1, and
PDCD4 gene relative expression levels in hepatoma cells
with hMSC and TGFβ-1 gene infected hMSC co-culture
groups were shown in the Table 1.
OPN gene relative quantitative expression of MHCC97-
H cell were significantly down-regulation after co-culturedwith hMSC (p < 0.05) and TGFβ-1 gene infected hMSC
groups (p < 0.01). But OPN gene relative quantitative
expression of MHCC97-L cell was only significantly
down-regulated after co-cultured with TGFβ-1 gene in-
fected hMSC groups (p < 0.01). Transforming growth
factor-β1 (TGFβ-1) gene relative quantitative expression
of MHCC97-H cell was significantly up-regulated after
co-cultured with hMSC (p < 0.05) and TGFβ-1 gene in-
fected hMSC groups (p < 0.01). TGFβ-1 gene relative
quantitative expression of MHCC97-L cell was also sig-
nificantly up-regulated after co-cultured with TGFβ-1
gene infected hMSC groups (p < 0.05). PDCD4 gene
relative quantitative expression of MHCC97-H cell was
significantly down-regulated after co-cultured with hMSC
but was significantly up-regulated after co-cultured TGFβ-1
gene infected hMSC groups (p < 0.05). PDCD4 gene rela-
tive quantitative expression of MHCC97-L cell was down-
regulated after co-cultured with hMSC and up-regulated
after co-cultured with TGFβ-1 gene infected hMSC groups.
But there were no statistical differences among groups.
Discussion
Hepatocellular cancer (HCC) remains a common cause
of cancer and death worldwide, especially in China.
HCC mortality is closely associated with primary organ
failure, metastasis, and recurrence after surgical resec-
tion. A hot new topic in medical treatment is the use of
mesenchymal stem cells (MSC) in treatment of HCC in
recent years [7]. Human bone marrow stem cells mainly
contain two cell types, including hematopoietic stem
cells (HSCs) and bone marrow mesenchymal stem cells
(hMSCs). The hMSCs play a multiple role in tumor
Fig. 4 TGFβ-1 infected hMSC co-culture with MHCC97-H cells proliferation test. OD value of TGFβ-1 infected hMSC co-culture with MHCC97-H cell
group was significantly higher than that of other groups (**p < 0.05). OD value of hMSC co-culture with MHCC97-H cell group was higher than
that of control group (*p < 0.05)
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cancer and liver cancer; (2) promotion of tumor growth,
such as in multiple myeloma and breast cancer; 3) no
obvious effect on tumor growth, such as in colon cancer.
In 1999, Petersen et al. for the first time reported that
liver oval cells and liver cells in rat can be differentiated
from bone marrow cells [4]. Sato et al. divided human
bone marrow cells into three types, including hMSCs,
CD34 cells, and hMSCs/CD34-cells. These three types
of cells were respectively transplanted into rat liver that
was injured by allyl ethanol, and hMSCs were the main
sources of hepatocytes in necrotic zone. Liver-specific
markers were observed in these cells, and cell fusion was
not observed [5]. Thereafter, in vivo and in vitro experi-
ments demonstrated that hMSCs can differentiate into
hepatocytes or hepatocyte-like cells [8].
So, aggregation of cells, both primary hepatoma cells
lines and hMSC, replicate the natural environment of
tumor stroma and permit an evaluation of the metastatic
behavior and treatment effects of tumor [9]. In our
study, all hMSC cells used were restrained within the
tenth generation, and these cells were identified using
surface antigens and inducing differentiation assay be-
fore using it. The hMSCs express CD29, CD44, and
CD105 but not CD45 and CD14. Furthermore, these
cells can differentiate to adipogenic cells, osteoblasts,
and chondrocyte. Hence, the hMSCs were in line with the
international standard [6]. MHCC97-H and MHCC97-LFig. 5 TGFβ-1 infected hMSC co-culture with MHCC97-L cells proliferation
group was significantly higher than that of other groups (**p < 0.05). OD va
that of control group (*p < 0.05)are liver cancer cell lines with different metastatic poten-
tial, constructed by the Liver Cancer Research Institute of
the Fudan University (Shanghai, China) [9, 10].
Moreover, experimental evidence in support of uses of
hMSC as vehicles of therapeutic genes is discussed. Be-
cause of its regenerative capacity and its particular im-
mune properties, the liver is a good model to analyze
the potential of MSC-based therapies. Finally, the poten-
tial application of hMSC and genetically modified hMSC
in HCC is proposed in view of available evidence [7]. So,
our study’s purpose is to observe the effects of hMSC
and genetically modified hMSC on different metastatic
potential hepatoma cells and xenograft models.
It has been reported [11, 12] that transforming growth
factor beta (TGFβ) is a multifunctional cytokine family,
which mainly plays roles in regulating cell proliferation,
differentiation, and embryo development, promoting the
formation of extracellular matrix and inhibiting immune
response. Among the members of this family, serum
TGFβ-1 is a principal isoform in humans, and it is
closely associated with the occurrence and development
of tumor. TGFβ-1 plays dual roles in inhibiting and pro-
moting tumor growth. At the early stage of tumorogenesis,
TGFβ-1 inhibited normal cell growth and tumorogenesis
by suppressing G1/S phase transition. However, the tumor
would not be sensitive to TGFβ-1 mediated growth inhib-
ition with the development of tumor. Therefore, based on
the hMSC is a good carrier for gene, our aim is to observetest. OD value of TGFβ-1 infected hMSC co-culture with MHCC97-L cell
lue of hMSC co-culture with MHCC97-L cell group was higher than
Fig. 6 MHCC97-H cells migration counting of before and after TGFβ-1 infected hMSC co-culture with MHCC97-H. The migration numbers of
hepatoma cells with TGFβ-1 infected hMSC co-culture groups were significantly reduced compared with those of the control group (*p < 0.05)
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experission on HCC in vitro, especially on the prolifera-
tion and invasion ability of tumor tissue or tumor cells.
Results showed that hMSC TGFβ-1 gene transduction
rate can reach more than 90 %. Reporter gene eGFP im-
aging showed that vectors carrying target gene se-
quences have been successfully imported hMSC. There
were not obvious difference on cell morphology between
hMSC and hMSC infected TGFβ-1 gene.
So, it is to observe the changes of proliferation and me-
tastasis ability, which the high expression TGFβ-1 of
hMSC by gene modified technology is on the different
metastatic potential hepatoma cells and xenograft models.
In this experiment, we successfully infected TGFβ-1 gene
to hMSC, which was high expression of TGFβ-1 cytokine.
This study demonstrated that the hepatoma cells pro-
liferation increased after these cells were co-cultured
with hMSC and TGFβ-1 gene transfection hMSC, sug-
gesting that hMSC that can promote the hepatoma cells
proliferation and exogenous TGFβ-1 (by TGFβ-1 gene
infected hMSC high expression) can also promote the
hepatoma cells proliferation. Indeed, qPCR results showed
that hepatoma cells expression TGFβ-1 in gene infected
hMSC and hMSC groups were higher than in control
groups. Our results were consistent with the findings of
researchers in Fudan University (Shanghai, China) [10].
Fierro et al. study indicated that hMSCs have effects onFig. 7 Cells migration counting of before and after TGFβ-1 infected hMSCs
with TGFβ-1 infected hMSC co-culture groups were significantly reduced c
hMSC co-culture group was significantly reduced compared with hMSC cotumor cells through paracrine mechanism. The hMSC
promoted tumor cells proliferation by secreting several
factors, including basic fibroblast growth factor (bFGF),
platelet derived growth factor B (PDGF-BB), transforming
β growth factor 1 (TGFβ-1), and vascular endothelial
growth factor (VEGF) [13]. Zhang, et al. found also that
TGFβ-1 in paracancerous liver tissue was positively corre-
lated with tumor size. Higher production of TGFβ-1 in
paracancerous liver tissue was always associated with big-
ger liver tumors [14]. So, TGFβ-1 gene infected hMSC can
still further promote cell proliferation than hMSC without
gene infection. Further, from the TGFβ-1 and PDCD4
gene expression by qPCR method, test results showed
hMSC promoted hepatoma cells proliferation but had no
obvious effect on hepatoma cells apoptosis. So, we can
draw a conclusion that the hMSC of infected TGFβ-1
gene can more obviously promote the hepatoma cells pro-
liferation and does not affect the hepatoma cells apoptosis.
We are speculating it might be the exogenous TGFβ-1
working. However, we still do not know exogenous TGFβ-
1 (by TGFβ-1 gene infected hMSC expression) or en-
dogenous TGFβ-1 (by hepatoma cells expression) the
differences of the biological mechanism in promoting
hepatoma cells proliferation.
The cells migration change represents the ability
changes of cells metastasis. Tumor cells migration break-
ing through is a vital step for tumor metastasis. Whenco-culture with MHCC97-L. The migration numbers of hepatoma cells
ompared with the other two groups (**p < 0.05), and TGFβ-1 infected
-culture group (*p < 0.05)
Fig. 8 The changes of HCC animal model tumors weight inhibition rate following engraftment of hMSC over time. The tumors weight inhibition
rates of MHCC97-H (blue) and MHCC97-L (green) animal models were the highest in the third week by hMSC engraftment
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groups in the experiment, our data suggested that hMSC
inhibited hepatoma cells migration and made metastatic
potential decrease, especially TGFβ-1 genetically modified
hMSC. But it was reported [15] that the exogenous TGFβ-
1 cytokine could promote tumor migration and metasta-
sis. How to explain this contrary results? It is worth
mentioning that OPN expression down-regulated after
hepatoma cells were co-cultured with hMSC and TGFβ-1
gene infected hMSC and may be used to explain meta-
static potential decrease. In the malignant setting, OPNFig. 9 The tumors weight inhibition rate changes of MHCC97-H and MHCC
over time. The tumors weight inhibition rate of MHCC97-H animal models
models were the highest in the fifth week by TGFβ-1 transfected hMSC enexpression by breast, colorectal, and hepatocellular cancer
cell lines stimulates primary tumor proliferation, migra-
tion, invasion, angiogenesis, and metastasis. OPN com-
bined with tumor cell surface integrins receptor promotes
tumor cell adhesion and extracellular matrix degradation
[16, 17]. OPN contains RGD (Arg-Gly-Asp) sequence,
which plays key roles in tumor invasion and metastasis.
Previous studies found that integrin mediated the adhesions
between HCC cell-cell interaction, as well as hepatoma cells
and extracellular matrix, respectively. Additionally, integ-
rin was involved in extracellular matrix degradation and97-L animal model following engraftment of TGFβ-1 transfected hMSC
(blue) was the highest in the fourth week and MHCC97-L (green) animal
graftment
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chemiotaxis) [18]. Another study showed that the effect of
hMSC that influences the hepatoma cells was by means of
OPN expression. Hepatoma cells grown with hMSCs for
12 h aggregated into cell clusters resembling hepato-
spheres. However, cluster formation was inhibited in cul-
tures with ablation of extracellular OPN and was also seen
in cell surface αvβ3 integrin blockade with RGD peptide.
Hepatospheres are organizing structures found in hepatic
cell culture [19]. So, in the absence of OPN expression,
cancer cells were less viable away from the primary tumor
environment and were less capable of metastases. No
doubt, further studies will be necessary to clarify the
underlying mechanisms and relationship of TGFβ-1,
OPN, and other biological factors.
The paper has carried out a preliminary study for the
hMSC intervention in xenograft models on the basis of
cytological studies [20]. The most important finding ob-
tained from the study is that the effectiveness of the
intervention of hMSCs on HCC with high-metastatic
potentials changes with time in animal models. The
highest inhibition on HCC was observed at third week
after hMSC engraftment. The highest tumor inhibition
rate of MHCC97-H animal models was observed in the
fourth week, and MHCC97-L animal models was ob-
served in the fifth week after TGFβ-1 infectedhMSC en-
graftment. It was the same that the tumor inhibition rate
gradually reduced with the prolongation of time. hMSC
and TGFβ-1 infected hMSC exhibit anti-tumor activity
in a time-dependent manner, and the activity against
HCC gradually reduces with the prolongation of time.
With regard to the intervention mechanism of hMSC
on HCC, studies have reported that hMSC are found to
colonize the liver of mouse models of orthotopic liver
transplantation and can differentiate into hepatocytes
that express albumin; in addition, the hMSCs are mainly
found in the marginal area of the tumor and rarely
present in tumors or normal liver tissues, and a large
necrotic area is observed in tumor tissues following
hMSC transplantation [21]. In addition to homogeneous
gene characteristics and multilineage differentiation po-
tential, hMSC also have a high efficacy of immunosup-
pression and anti-infection activity, and the characteristics
of migration to inflammatory tissues and remodeling tis-
sues (homing characteristic), which accelerate the repair
of injured liver tissues, inhibit immune responses and con-
fer anti-hepatic fibrosis functions [22]. However, prior to
this work, to the best of our knowledge, there have been
no reports on hMSC anti-tumor activity in a time-
dependent manner.
Conclusions
Our studies demonstrated that hMSC and TGFβ-1 gene
infected hMSC can promote the different metastaticpotential hepatoma cells proliferation and inhibit differ-
ent metastatic potential hepatoma cells migration. In the
animal models test, we demonstrated that hMSC and
TGFβ-1 gene infected hMSC exhibit anti-tumor activity
in a time-dependent manner, and the activity against
HCC gradually reduces with the prolongation of time.
TGFβ-1 cytokine may be mainly factor in HCC prolifer-
ation. OPN makes a significant contribution to the
changes of hepatoma cells migration. Whether gene
modified hMSC as a novel method to intervene the dif-
ferent metastatic potential HCC is the focus of future
work.
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